Liquidia Corp (LQDA)
As of Sep 19, 2026, Liquidia Corp (LQDA) scores 2.7/10 on AlphaStocks' five-model composite, #161 of 168 Health Care stocks.
Health Care / Pharmaceuticals
S&P SmallCap 600$66.87
Scores poorly across most models. Proceed with caution.
Avoid
Score based on 3 of 5 models — limited data
Data as of Sep 19, 2026
Is Liquidia Corp a Good Investment in 2026?
Liquidia Corp (LQDA) scores 2.7 out of 10 on AlphaStocks' composite model, earning a Avoid rating. The Piotroski model is the most favorable, rating Liquidia Corp as Neutral. However, the Graham model rates it Caution. Liquidia Corp ranks #161 out of 168 stocks in the Health Care sector.
This summary is algorithmically generated and is not financial advice.
Key Metrics
Valuation
Currently unprofitable — fair value estimate not available.
Fair value estimate not available for this stock.
5-Model Analysis
Each model evaluates this stock from a different angle. Combined, they form the composite score above.
Piotroski
Neutral
4/9
Buffett
Caution
Business quality & competitive moat
Graham
Caution
Price vs intrinsic value
Lynch
Limited Data
Growth rate vs price (PEG)
Greenblatt
Limited Data
Earnings yield + return on capital
Frequently Asked Questions
Is Liquidia Corp (LQDA) a good investment?
What is Liquidia Corp's Piotroski F-Score?
Is LQDA overvalued or undervalued?
How does LQDA compare to other Health Care stocks?
What do investment models say about LQDA?
Similar Stocks
Compare LQDA with
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer